Thursday, November 10, 2011
NeuroDerm Ltd., of Ness Ziona, Israel, reported that ND0611 met all primary and secondary endpoints in a Phase I/II safety and pharmacokinetic trial as an adjunct therapy in advanced Parkinson's disease. The drug is administered subcutaneously by a dermal patch and is designed to increase the bioavailability and efficacy of orally administered levodopa, as in Sinemet, Sinemet CR or Stalevo.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.